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Background: Although recent federal mandate provides financial incentives for physicians to use electronic prescribing (e-prescribing), clinical 
endpoints to support its use are lacking. As prior studies have shown that e-prescribing leads to better patient adherence, we assessed the 
hypothesis that e-prescribing would enhance attainment of patients’ National Cholesterol Education Program Adult Treatment Program III (ATP III) 
guidelines-based low-density lipoprotein (LDL) goals.
Methods: In this retrospective cohort study, we queried the electronic medical records (Allscripts EHR) of a multi-specialty outpatient academic 
medical practice to identify patient encounters during which a lipid panel was drawn in 2007 (n=21,860). All physicians used the EHR and had the 
option to use e-prescribing. The EHR did not include a clinical decision tool for guideline adherence. Medical records with sufficient information to 
determine the ATP III LDL goal were available for 8395 patients; 2567 patients returned for a follow-up lipid panel within the same year. Logistic 
regression analysis was used to examine whether the odds of reaching LDL goal were influenced by e-prescribing and adjusted for provider 
characteristics known to affect prescribing patterns (age, specialty, board certification status), type of insurance, patient age and sex.
Results: Upon initial presentation, 64.7% of patients were at their LDL goal. At follow-up, 75.2% of patients were at goal. Lipid-lowering intervention 
was done by e-prescribing in 46.1% of patients, manual prescription in 42.3%, and no medication in 11.6%. Provider characteristics, insurance type, 
patient age and sex had no effect upon the likelihood of LDL goal attainment at follow-up or percent change in LDL. However, use of e-prescribing 
had an odds ratio of 1.49 (95% CI: 1.08-2.06) for LDL goal attainment, and LDL levels changed from initial visit to follow-up by -6.7% with 
e-prescribing vs. -0.3% (p<0.0001).
Conclusion: Our study is the first to demonstrate that e-prescribing can positively affect LDL goal attainment. Beyond financial incentives, 
e-prescribing can deliver tangible clinical gains, likely as a consequence of improved patient adherence.
